Table 1 Correlations between STK10 expression and clinicopathological features in AML from TCGA cohort
Characteristics | STK10 expression | P value | |
|---|---|---|---|
Low (n = 75) | High (n = 76) | ||
Sex, male/female | 43/32 | 40/36 | 0.677 |
Age, n (%) | Â | Â | 0.025 |
 ≤ 60 | 51 (33.8%) | 37 (24.5%) |  |
 > 60 | 24 (15.9%) | 39 (25.8%) |  |
WBC (109/L), meidan (Q1–Q3) | 14 (4, 41.5) | 26 (6, 75.5) | 0.075 |
BM blasts(%), meidan (Q1–Q3) | 40 (5, 64) | 36 (11, 64.75) | 0.518 |
PB blasts(%), meidan (Q1–Q3) | 72 (49.5, 85.5) | 71 (50.75, 84.25) | 0.863 |
Cytogenetic risk, n (%) |  |  | < 0.001 |
 Favorable | 27 (18.1%) | 4 (2.7%) |  |
 Intermediate | 31 (20.8%) | 51 (34.2%) |  |
 Poor | 16 (10.7%) | 20 (13.4%) |  |
FAB classifications, n (%) | Â | Â | 0.183 |
 M0 | 7 (4.7%) | 8 (5.3%) |  |
 M1 | 12 (8%) | 23 (15.3%) |  |
 M2 | 20 (13.3%) | 18 (12%) |  |
 M3 | 12 (8%) | 3 (2%) |  |
 M4 | 14 (9.3%) | 15 (10%) |  |
 M5 | 7 (4.7%) | 8 (5.3%) |  |
 M6 | 1 (0.7%) | 1 (0.7%) |  |
 M7 | 1 (0.7%) | 0 (0%) |  |